IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-HLA Antibodies After Lung Transplantation
Authors:
Open Access
- 1 December 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (12) , 2682-2692
Abstract
At our institution, until April 2013, patients who showed early donor specific anti-HLA antibodies (DSA) after lung transplantation were preemptively treated with therapeutic plasma exchange (tPE) and a single dose of Rituximab. In April 2013, we moved to a therapy based on IgM-enriched human immunoglobulins (IVIG), repeated every 4 weeks, and a single dose of Rituximab. This observational study was designed to evaluate the short-term patient and graft survival in patients who underwent IVIG-based DSA treatment (group A, n = 57) versus contemporary patients transplanted between April 2013 and January 2015 without DSA (group C, n = 180), as well as to evaluate DSA clearance in IVIG-treated patients versus historic patients who had undergone tPE-based treatment (group B, n = 56). Patient records were retrospectively reviewed. Follow-up ended on April 1, 2015. At 6 months and 1 year of follow-up, group A had a survival similar to group C (P = 0.81) but better than group B (P = 0.008). Group A showed statistically nonsignificant trends toward improved freedom from pulsed-steroid therapy and biopsy-confirmed rejection over groups B and C. The DSA clearance was better in group A than group B at treatment end (92% vs 64%; P = 0.002) and last DSA control (90% vs 75%; P = 0.04). Patients with new early DSA but without graft dysfunction that are treated with IVIG and Rituximab have similarly good early survival as contemporary lung transplant recipients without early DSA. The IVIG yielded increased DSA clearance compared with historic tPE-based treatment, yet spontaneous clearance of new DSA also remains common.Keywords
This publication has 37 references indexed in Scilit:
- Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantationKidney International, 2015
- Assessing Antibody Strength: Comparison of MFI, C1q, and Titer InformationAmerican Journal of Transplantation, 2015
- Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantationThe Journal of Heart and Lung Transplantation, 2015
- Antibody-Mediated Rejection in Lung TransplantationTransplantation, 2014
- Acute antibody-mediated rejection after lung transplantationThe Journal of Heart and Lung Transplantation, 2013
- Cyclosporine or Tacrolimus: Which Is the Better Partner for Myfortic or CellCept?Transplantation Proceedings, 2012
- Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantationExpert Review of Clinical Immunology, 2011
- Summary of FDA Antibody-Mediated Rejection WorkshopAmerican Journal of Transplantation, 2011
- Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantationThe Journal of Heart and Lung Transplantation, 2010
- The emerging role of rituximab in organ transplantationTransplant International, 2006